vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v11i1.130vsp-508Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESСРАВНИТЕЛЬНАЯ ЭФФЕКТИВНОСТЬ РИТУКСИМАБА И МОНОТЕРАПИИ МЕТОТРЕКСАТОМ В СТАНДАРТНЫХ ДОЗАХ У БОЛЬНЫХ ТЯЖЕЛЫМ СИСТЕМНЫМ ЮВЕНИЛЬНЫМ ИДИОПАТИЧЕСКИМ АРТРИТОМ (ПРЕДВАРИТЕЛЬНЫЕ РЕЗУЛЬТАТЫ)COMPARATIVE EFFICACY OF RITUXIMAB AND METHOTREXATE MONOTHERAPY IN STANDARD DOSES IN PATIENTS WITH SEVERE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (PRELIMINARY RESULTS)АлексееваЕ. И.AlexeevaE. I.

доктор медицинских наук, профессор, декан педиатрического факультета Первого МГМУ им. И.М. Сеченова, заведующая ревматологическим отделением Научного центра здоровья детей РАМН

Ekaterina Iosifovna Alexeeva, PhD, professor, Head of the Pediatric Department of I.M. Sechenov First MSMU, Head of the Rheumatologic Department of SCCH of RAMS

alekatya@ya.ruВалиеваС. И.ValievaS. I.alekatya@ya.ruДенисоваР. В.DenisovaR. V.alekatya@ya.ruБзароваТ. М.BzarovaT. M.alekatya@ya.ruИсаеваК. Б.IsaevaK. B.alekatya@ya.ruМитенкоЕ. В.MitenkoE. V.alekatya@ya.ruСлепцоваТ. В.SleptsovaT. V.alekatya@ya.ruЧистяковаЕ. Г.ChistyakovaE. G.alekatya@ya.ruНаучный центр здоровья детей РАМН, Москва; Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children’s Health RAMS, Moscow; Sechenov First Moscow Medical UniversityRussian FederationНаучный центр здоровья детей РАМН, МоскваРоссияScientific Centre of Children’s Health RAMS, MoscowRussian Federation201215012012111Вопросы современной педиатрии3745Copyright © Алексеева Е.И., Валиева С.И., Денисова Р.В., Бзарова Т.М., Исаева К.Б., Митенко Е.В., Слепцова Т.В., Чистякова Е.Г., 20122012Алексеева Е.И., Валиева С.И., Денисова Р.В., Бзарова Т.М., Исаева К.Б., Митенко Е.В., Слепцова Т.В., Чистякова Е.Г.Alexeeva E.I., Valieva S.I., Denisova R.V., Bzarova T.M., Isaeva K.B., Mitenko E.V., Sleptsova T.V., Chistyakova E.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/508

В статье представлены результаты сравнительного исследования эффективности ритуксимаба и метотрексата у детей с системным ювенильным идиопатическим артритом. В исследование было включено 115 детей в возрасте от 2 до 16 лет: в основную группу вошло 75 детей, лечившихся ритуксимабом, в группу сравнения — 40 больных, получавших метотрексат в средней дозе. Терапия ритуксимабом оказалась достоверно эффективней, чем метотрексатом в стандартных дозах. Отчетливое улучшение у детей, лечившихся ритуксимабом, наблюдалось уже через 12 нед. В эти сроки у 90% больных купировались опасные для жизни системные проявления, снизились активность суставного синдрома и лабораторные показатели. Через 24 нед наблюдалось достоверное снижение активности болезни, улучшение функциональной способности суставов и снижение степени инвалидизации детей. У 25% пациентов была зарегистрирована стадия неактивной болезни. У детей группы сравнения продолжали рецидивировать системные проявления, персистировал активный артрит, высокие лабораторные показатели, прогрессировала инвалидность.

системный ювенильный идиопатический артритритуксимабметотрексатдетsystemic idiopathic juvenile arthritisrituximabmethotrexatechildrenReferencesCassidy J. T., Petty R. E. Juvenile idiopathic arthritis. In Cassidy J. T., Petty R. E. eds. Textbook of pediatric rheumatology, 5th edn. Philadelphia: WB Saunders, 2005.Cassidy J. T., Petty R. E. Juvenile idiopathic arthritis. In Cassidy J. T., Petty R. E. eds. Textbook of pediatric rheumatology, 5th edn. Philadelphia: WB Saunders, 2005.Алексеева Е. И., Валиева С. И., Бзарова Т. М. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного ревматоидного артрита // Вопросы современной педиатрии. — 2009; 8 (5): 14–25.Алексеева Е. И., Валиева С. И., Бзарова Т. М. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного ревматоидного артрита // Вопросы современной педиатрии. — 2009; 8 (5): 14–25.Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / под общей ред. акад. РАМН, проф. А. А. Баранова. — М., 2007. — 368 с.Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / под общей ред. акад. РАМН, проф. А. А. Баранова. — М., 2007. — 368 с.Tambic-Bukovac L., Malcic I., Prohic A. Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis // Rheumatism. — 2002; 49 (1): 20–24.Tambic-Bukovac L., Malcic I., Prohic A. Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis // Rheumatism. — 2002; 49 (1): 20–24.Cassidy J. T. Outcomes research in the therapeutic use of methotrexate in children with chronic peripheral arthritis // J. Pediatr. — 1998; 133: 179–180.Cassidy J. T. Outcomes research in the therapeutic use of methotrexate in children with chronic peripheral arthritis // J. Pediatr. — 1998; 133: 179–180.Ramanan A. V., Whitworth P., Baildam E. M. Use of methotrexate in juvenile idiopathic arthritis // Arch. Dis. Child. — 2003; 88: 197–200.Ramanan A. V., Whitworth P., Baildam E. M. Use of methotrexate in juvenile idiopathic arthritis // Arch. Dis. Child. — 2003; 88: 197–200.Yokota S. Classification and treatment strategy for juvenile idiopathic arthritis // Therapy. — 1999; 81: 766–772.Yokota S. Classification and treatment strategy for juvenile idiopathic arthritis // Therapy. — 1999; 81: 766–772.Giannini E. H., Brewer E. J., Kuzmina N. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group // N. Engl. J. Med. — 1992; 326: 1043–1049.Giannini E. H., Brewer E. J., Kuzmina N. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group // N. Engl. J. Med. — 1992; 326: 1043–1049.Woo P., Southwood T. R., Prieur A. M. et al. Randomized, pla cebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis // Arthr. Rheum. — 2000; 43 (8): 1849–1857.Woo P., Southwood T. R., Prieur A. M. et al. Randomized, pla cebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis // Arthr. Rheum. — 2000; 43 (8): 1849–1857.Ruperto N., Murray K. J., Gerloni V. et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate // Arthritis Rheum. — 2004; 50: 2191–2201.Ruperto N., Murray K. J., Gerloni V. et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate // Arthritis Rheum. — 2004; 50: 2191–2201.Tukova J., Chladek J., Nemcova D. et al. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis // Clin. Exp. Rheumatol. — 2009; 27 (6): 1047–1053.Tukova J., Chladek J., Nemcova D. et al. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis // Clin. Exp. Rheumatol. — 2009; 27 (6): 1047–1053.Alsufyani K., Ortiz-Alvarez O., Cabral D. A. et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate // J. Rheumatol. — 2004; 31 (1): 179–182.Alsufyani K., Ortiz-Alvarez O., Cabral D. A. et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate // J. Rheumatol. — 2004; 31 (1): 179–182.Woo P., Southwood T. R., Prieur A. M. et al. Randomised placebocontrolled crossover trial with low dose oral methotrexate in children with extended oligoarticular or systemic arthritis // Arthritis Rheum. — 2000; 43: 1849–1857.Woo P., Southwood T. R., Prieur A. M. et al. Randomised placebocontrolled crossover trial with low dose oral methotrexate in children with extended oligoarticular or systemic arthritis // Arthritis Rheum. — 2000; 43: 1849–1857.Beukelman T., Patkar N. M., Saag K. G. et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features // Arthritis Care Res (Hoboken). — 2011; 63: 465–482.Beukelman T., Patkar N. M., Saag K. G. et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features // Arthritis Care Res (Hoboken). — 2011; 63: 465–482.Noorchashm H., Noorchashm N., Kern J., Rostami S. Y., Barker C. F., Naji A. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice // Diabetes. — 1997; 46: 941–946.Noorchashm H., Noorchashm N., Kern J., Rostami S. Y., Barker C. F., Naji A. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice // Diabetes. — 1997; 46: 941–946.Chan O. T., Hannum L. G., Haberman A. M., Madaio M. P., Shlom chik M. J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus // J. Exp. Med. — 1999; 89: 1639–1648.Chan O. T., Hannum L. G., Haberman A. M., Madaio M. P., Shlom chik M. J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus // J. Exp. Med. — 1999; 89: 1639–1648.Takemura S., Braun A., Crowson C. et al. Lymphoid neogenesis in rheumatoid synovitis // J. Immunol. — 2001; 167: 1072–1080.Takemura S., Braun A., Crowson C. et al. Lymphoid neogenesis in rheumatoid synovitis // J. Immunol. — 2001; 167: 1072–1080.O’Neill S. K., Shlomchik M. J., Glant T. T. et al. Antigenspecific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis // J. Immunol. — 2005; 174: 3781–3788.O’Neill S. K., Shlomchik M. J., Glant T. T. et al. Antigenspecific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis // J. Immunol. — 2005; 174: 3781–3788.Anolik J. H., Barnard J., Cappione A. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus // Arthritis Rheum. — 2004; 50: 3580–3590.Anolik J. H., Barnard J., Cappione A. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus // Arthritis Rheum. — 2004; 50: 3580–3590.Wallace C. A., Sherry D. D. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis // J. Rheumatol. — 1992; 19: 1604–1607.Wallace C. A., Sherry D. D. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis // J. Rheumatol. — 1992; 19: 1604–1607.Reiff A., Shaham B., Wood B. P., Bernstein B. H., Stanley P., Szer I. S. High dose methotrexate in the treatment of refractoryReiff A., Shaham B., Wood B. P., Bernstein B. H., Stanley P., Szer I. S. High dose methotrexate in the treatment of refractoryjuvenile rheumatoid arthritis // Clin. Exp. Rheumatol. — 1995; 13: 113–118.juvenile rheumatoid arthritis // Clin. Exp. Rheumatol. — 1995; 13: 113–118.Balint G., Gergely P. Clinical immunotoxicity of antirheumatic drugs // Inflamm. Res. — 1996; 45: S91–95.Balint G., Gergely P. Clinical immunotoxicity of antirheumatic drugs // Inflamm. Res. — 1996; 45: S91–95.Flato B., Vinje O., Forre O. Toxicity of antirheumatic and anti-inflammatory drugs in children // Clin. Rheumatol. — 1998; 17: 505–510.Flato B., Vinje O., Forre O. Toxicity of antirheumatic and anti-inflammatory drugs in children // Clin. Rheumatol. — 1998; 17: 505–510.SmolenKeystone E. C., Emery P. et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis // Ann. Rheum. Dis. — 2007; 66: 143–150.SmolenKeystone E. C., Emery P. et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis // Ann. Rheum. Dis. — 2007; 66: 143–150.Chatzidionysiou K., Lie E., Nasonov E. et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries // Ann. Rheum. Dis. — 2011; 70 (9): 1575–1580.Chatzidionysiou K., Lie E., Nasonov E. et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries // Ann. Rheum. Dis. — 2011; 70 (9): 1575–1580.Edwards J. C., Szczepanski L., Szechinski J. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis // N. Engl. J. Med. — 2004; 350: 2572–2581.Edwards J. C., Szczepanski L., Szechinski J. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis // N. Engl. J. Med. — 2004; 350: 2572–2581.Emery P., Fleischmann R., Filipowicz-Sosnowska A. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial // Arthritis Rheum. — 2006; 54: 1390–1400.Emery P., Fleischmann R., Filipowicz-Sosnowska A. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial // Arthritis Rheum. — 2006; 54: 1390–1400.Cohen S. B., Emery P., Greenwald M. W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks // Arthritis Rheum. — 2006; 54: 2793–2806.Cohen S. B., Emery P., Greenwald M. W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks // Arthritis Rheum. — 2006; 54: 2793–2806.van Vollenhoven R. F., Emery P., Bingham C. O. et al. Long term safety of patients receiving rituximab in rheumatoid arthritis clinical trials // J. Rheumatol. — 2010; 37: 558–567.van Vollenhoven R. F., Emery P., Bingham C. O. et al. Long term safety of patients receiving rituximab in rheumatoid arthritis clinical trials // J. Rheumatol. — 2010; 37: 558–567.Rubbert-Roth A., Tak P. P., Zerbini C. et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR) // Rheumatology (Oxford). — 2010; 49: 1683–1693.Rubbert-Roth A., Tak P. P., Zerbini C. et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR) // Rheumatology (Oxford). — 2010; 49: 1683–1693.Emery P., Deodhar A., Rigby W. F. et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebocontrolled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) // Ann Rheum Dis. — 2010; 69: 1629–1635.Emery P., Deodhar A., Rigby W. F. et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebocontrolled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) // Ann Rheum Dis. — 2010; 69: 1629–1635.Tak P. P., Rigby W. F., Rubbert-Roth A. et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial // Ann. Rheum. Dis. — 2011; 70: 39–46.Tak P. P., Rigby W. F., Rubbert-Roth A. et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial // Ann. Rheum. Dis. — 2011; 70: 39–46.Loveless J. E., Olech E., Pritchard C. et al. An open-label, prospective study (SUNDIAL) of the safety of rituximab in combination with disease-modifying anti-rheumatic drugs in patients with active rheumatoid arthritis (SUNDIAL) // Arthritis Rheum. — 2009; 60: S1660.Loveless J. E., Olech E., Pritchard C. et al. An open-label, prospective study (SUNDIAL) of the safety of rituximab in combination with disease-modifying anti-rheumatic drugs in patients with active rheumatoid arthritis (SUNDIAL) // Arthritis Rheum. — 2009; 60: S1660.Kuek A., Hazleman B. L., Gaston J. H. et al. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab // Rheumatology (Oxford). — 2006; 45: 1448–1449.Kuek A., Hazleman B. L., Gaston J. H. et al. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab // Rheumatology (Oxford). — 2006; 45: 1448–1449.Foeldvari I., Bica B., Dedeoglu F. Efficacy of rituximab in rf factor negative juvenile idiopathic arthritis [FRI0450] // Ann. Rheum. Dis. — 2009; 68 (Suppl. 3): 502.Foeldvari I., Bica B., Dedeoglu F. Efficacy of rituximab in rf factor negative juvenile idiopathic arthritis [FRI0450] // Ann. Rheum. Dis. — 2009; 68 (Suppl. 3): 502.Алексеева Е. И., Валиева С. И., Бзарова Т. М. и др. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного артрита // Вопросы современной педиатрии. — 2009; 8 (5): 19–30.Алексеева Е. И., Валиева С. И., Бзарова Т. М. и др. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного артрита // Вопросы современной педиатрии. — 2009; 8 (5): 19–30.Alexeeva E. I., Valieva S. I., Bzarova T. M. et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis // Clin Rheumatol. — 2011; 9 (30): 1163–1172Alexeeva E. I., Valieva S. I., Bzarova T. M. et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis // Clin Rheumatol. — 2011; 9 (30): 1163–1172

The authors declare that there are no conflicts of interest present.